The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Targeting EGFR Ex20 mutant lung cancer with the wild type sparing kinase inhibitor PRB001.
 
Martin L. Sos
Research Funding - Novartis
 
Hannah Lea Tumbrink
No Relationships to Disclose
 
Carsten Schultz-Fademrecht
Employment - Lead Discovery Center; PearlRiver Bio
Patents, Royalties, Other Intellectual Property - Lead Discovery Center
 
Jonas Lategahn
Patents, Royalties, Other Intellectual Property - TU Dortmund University; TU Dortmund University (Inst)
Other Relationship - PearlRiver Bio
 
Marina Keul
Patents, Royalties, Other Intellectual Property - TU Dortmund University
 
Janina Niggenaber
Patents, Royalties, Other Intellectual Property - TU Dortmund University; TU Dortmund University (Inst)
 
Alena Heimsoeth
No Relationships to Disclose
 
Matthias Baumann
Employment - Lead Discovery Center
Patents, Royalties, Other Intellectual Property - Lead Discovery Center (Inst)
Travel, Accommodations, Expenses - Lead Discovery Center
 
Lisa Hanna Werr
No Relationships to Disclose
 
Carsten Degenhart
Employment - Lead Discovery Center
Research Funding - Lead Discovery Center
Patents, Royalties, Other Intellectual Property - Lead Discovery Center
 
Sascha Menninger
Employment - Lead Discovery Center
Research Funding - Lead Discovery Center
 
Johannes M Heuckmann
Employment - NEO New Oncology
Leadership - NEO New Oncology
Stock and Other Ownership Interests - Bayer; BB Biotech Ventures; Johnson & Johnson; Novartis; Siemens Healthineers
Patents, Royalties, Other Intellectual Property - NEO New Oncology
Other Relationship - Co-founder of PearlRiverBio (company in formation)
 
Roman K. Thomas
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Johnson & Johnson; Merck; Roche; Siemens
Honoraria - Siemens
Consulting or Advisory Role - NEO New Oncology
Research Funding - Roche (Inst)
Patents, Royalties, Other Intellectual Property - IP owned by the University of Cologne (Inst)
 
Daniel Rauh
Stock and Other Ownership Interests - MorphoSys; MorphoSys (I)
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; Novartis; Pfizer; Sanofi; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Pfizer
Research Funding - Johnson & Johnson (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - TU Dortmund University; TU Dortmund University (Inst)
Expert Testimony - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bayer; Novartis; Pfizer; Sanofi
Other Relationship - PearlRiver Bio
 
Bert Klebl
Research Funding - Lead Discovery Center (Inst)
Patents, Royalties, Other Intellectual Property - Lead Discovery Center (Inst)
Other Relationship - Spin-Out in preparation